Eisai and Biogen Publishes Results of P-III Study (Clarity AD) of Lecanemab for Early Alzheimer's Disease
Shots:
- In the P-III study participants (n=1795) were randomly assigned in 1:1 to receive lecanemab (10 mg/kg Q2W, IV, n=898) or PBO (n=897) and results were published in the New England Journal of Medicine
- The result showed the mean CDR-SB score at baseline was ~3.2 in both groups, the adjusted least-squares mean change from baseline @18mos. was (1.21 vs 1.66) also greater reduction were observed in brain amyloid burden with lecanemab vs. PBO
- Lecanemab (BAN2401), an anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer's disease with confirmed presence of amyloid pathology in the brain
Ref: PRNewswire | Image: Biogen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
